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Suppression of experimental abdominal aortic
aneurysms in mice by treatment with pyrrolidine
dithiocarbamate, an antioxidant inhibitor of
nuclear factor-B
Federico E. Parodi, MD,a Dongli Mao, MD,a Terri L. Ennis, BS,a Michel A. Bartoli, MD,a,b and
Robert W. Thompson, MD,a,c,d St Louis, Mo; and Marseille, France
Objective:Proinflammatory cytokines andmatrixmetalloproteinases (MMPs) are prominentmediators of the connective tissue
destruction that characterizes abdominal aortic aneurysms (AAAs), and nuclear factor (NF)-B is a cytokine-responsive
transcription factor that promotes macrophage MMP expression. The purpose of this study was to determine whether
aneurysmal degeneration is influenced by pyrrolidine dithiocarbamate (PDTC), a pharmacologic inhibitor of NF-B.
Methods: Adult male C57BL/6 mice underwent transient elastase perfusion of the abdominal aorta to induce the
development of AAAs. Animals were treated every 48 hours by intraperitoneal injection with either saline (n  34) or
PDTC 20 mg/kg (n  49). Aortic diameter (AD) measurements were used to determine the extent of aortic dilatation
before and immediately after elastase perfusion and again at day 14.
Results: All saline-treated mice developed AAAs associated with mononuclear inflammation and destruction of medial
elastin (overall increase in AD, mean  SEM, 169.1%  7.5%). In contrast, the incidence of AAAs was only 63% in
PDTC-treated mice, with a reduction in the overall increase in AD to 109.8%  4.2% (P < .0001 vs saline), decreased
inflammation, and structural preservation of aortic wall connective tissue. Although aneurysm development in saline-
treated mice was associated with a marked increase in aortic tissue NF-B and activator protein 1 DNA-binding activities,
both activities were substantially reduced in PDTC-treated animals. PDTC-treatedmice also exhibited significantly lower
serum and aortic wall concentrations of interleukin 1 and interleukin 6, as well as lower amounts of aortic wall MMP-9,
as compared with saline-treated controls.
Conclusions: Treatment with PDTC inhibits elastase-induced experimental AAAs in the mouse, along with suppression of
aortic wall NF-B and activator protein 1 transcription factor activities, reduced expression of proinflammatory
cytokines, and suppression of MMP-9. NF-B is therefore a potentially important therapeutic target for the suppression
of aneurysmal degeneration. (J Vasc Surg 2005;41:479-89.)
Clinical Relevance:Development andprogressionof humanAAAs is associatedwith inflammation and enzymatic degradation
of connective tissue proteins. MMP-9 is one of the enzymes involved in aneurysm disease, and its production may be induced
in part by activation of the transcription factor NF-B. In this mouse model, treatment with pyrrolidine dithiocarbamate (a
pharmacologic inhibitor ofNF-B) acted to suppressMMP-9 and aneurysmdevelopment. It is hoped that treatment strategies
that target NF-B may eventually be shown to suppress the growth of small aortic aneurysms in patients.Abdominal aortic aneurysms (AAAs) are characterized
by chronic transmural inflammation and destructive re-
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tory infiltrates in AAAs are dominated by macrophages and
T lymphocytes,4 which produce and respond to various
mediators, including chemokines, cytokines, prostaglan-
dins, and reactive oxygen species (ROS).5-8 Macrophages
in aneurysm tissue are also the principal source of matrix
metalloproteinases (MMPs), a family of zinc-dependent
enzymes capable of degrading elastin and interstitial colla-
gen, the primary structural proteins of the aortic wall.9,10
Investigations in several animal models of aortic aneurysm
have demonstrated that increased macrophage expression
of MMP-9 plays a critical role in the development and
progression of AAAs: suppression of aneurysmal degenera-
tion has been observed in animals treated with nonspecific
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expression of tissue inhibitor of metalloproteinases 115 and
in mice with targeted deletion of the MMP-9 gene.16,17
Further understanding of the mechanisms that stimulate
and regulate aortic wall expression of MMP-9 is therefore
important for the development of novel therapeutic strate-
gies for aneurysmal disease.
MMP-9 is known to exhibit developmental and tissue-
specific patterns of expression distinct from those of other
MMPs, consistent with unique mechanisms of transcrip-
tional regulation.18,19 MMP-9 is encoded by a 7.7-kilobase
gene located on mouse chromosome 2, which consists of
13 exons that correspond in size to the human gene.20 The
5=-flanking regions of the mouse and humanMMP-9 genes
are characterized by a number of conserved transcriptional
control elements, including a TATA box, two to four
activator protein (AP)-1 sites, four PEA3/ets sites, three
Sp1 sites, several CA-repeat microsatellite regions, an AP-2
site, and a nuclear factor-B (NF-B) bindingmotif located
527 to519 base pairs (bp) upstream from the transcrip-
tion start site.20-24 Like the promoters for other MMP
genes, the AP-1 site located in closest proximity to the
transcription start site (50 to 44 bp) is thought to be
indispensable for basal and cytokine-induced MMP-9 tran-
scription, whereas the NF-B and other sites exert addi-
tional modulating effects on inducible MMP-9 gene
expression.18,19 Although the importance of NF-B in
activating maximal MMP-9 expression has been demon-
strated in a variety of normal and transformed cells in
vitro,25-29 the functional role of this pathway has only
recently been examined in animal models of AAAs.30,31
In addition to endogenous mechanisms of regula-
tion,32,33 cellular NF-B activity can be inhibited by a
variety of different drugs, including salicylates, nonsteroidal
anti-inflammatory agents, glucocorticosteroids, protea-
some inhibitors, antioxidants, and selective peptide antag-
onists.34,35 Pyrrolidine dithiocarbamate (PDTC) is an an-
tioxidant compound that specifically suppresses NF-B
activity in both cultured cells and in vivo studies.36-41 To
assess the functional role of NF-B activation in the patho-
physiology of aneurysmal degeneration, the purpose of this
study was to determine how treatment with PDTC influ-
ences the development of experimental AAAs in themouse.
METHODS
Experimental animals and drug treatment. Adult
male C57BL/6J mice were purchased from The Jackson
Laboratory (Bangor, Me). Mice in the experimental group
(n  49) were treated by intraperitoneal injection of 0.03
mL of saline solution containing PDTC 20 mg/kg (Sigma
Chemical Company, St Louis,Mo), beginning 1 day before
elastase perfusion and continuing every 48 hours for the
entire 14-day experimental period, on the basis of previous
studies showing the effectiveness of PDTC in other mouse
models of inflammatory disease at doses ranging from 10 to
100 mg/kg.38,41 The control group consisted of 34 mice
treated by intraperitoneal injection of saline solution alone
according to the same schedule. All experimental proce-dures were performed according to a protocol approved by
the Animal Studies Committee at Washington University
School of Medicine.
Elastase perfusion model and aortic diameter
measurements. All mice were subjected to transient per-
fusion of the abdominal aorta with type I porcine pancreatic
elastase to induce the development of AAAs, as described in
Appendix I (online only) and in previous reports.16 At the
time of elastase perfusion, the preperfusion aortic diameter
(AD Pre) was measured with the assistance of an operating
stereomicroscope (Leica, Deerfield, Ill) and a calibrated
ocular grid, and the postperfusion AD (AD Post) was
measured 5 minutes after flow was restored to the lower
extremities. Final AD measurements (AD Final) were ob-
tained during repeat laparotomy 14 days after the initial
elastase perfusion procedure, before mice were killed and
tissue was procured. For each animal, the extent of imme-
diate aortic dilation was calculated as the percentage in-
crease between the preperfusion and postperfusion AD
measurements (AD Pre¡ Post), and the extent of inter-
val aortic dilation was calculated as the percentage increase
between the postperfusion and final AD measurements
(AD Post¡ Final). The extent of overall aortic dilatation
was calculated as the percentage increase between the
preperfusion and final AD measurements (AD Pre ¡
Final). AAAs were defined as an overall extent of aortic
dilatation greater than 100%.
Light microscopy. Specimens of the abdominal aorta
were excised after systemic perfusion/fixation with 10%
neutral buffered formalin (120mmHg for 10minutes) and
embedded in paraffin. Cross sections of aortic tissue (5m)
were stained with Verhoeff-van Gieson for elastin and
examined by light microscopy. Sections from three animals
in each group were scored for the extent of inflammation
and elastin content by four different observers unaware of
the experimental group by using a one- to five-point scale,
and themean SEMhistologic scores were determined for
comparisons between PDTC- and saline-treated mice by
using the unpaired t test.
Electrophoretic gel shift assays. Double-stranded
oligodeoxynucleotide DNA probes were prepared that cor-
responded to the murine recognition elements for NF-B
(sense strand, 5=-AGT TGA GGG GAC TTT CCC AGG
C-3=) and AP-1 (sense strand, 5=-CGC TTG ATG ACT
CAGCCGGAA-3=), along with nonbinding mutant DNA
probes as controls (NF-B mutant sense strand, 5=-AGT
TGA GGc GAC TTT CCC AGG C-3=; AP-1 mutant sense
strand, 5=-CGC TTG ATG ACT tgG CCG GAA-3=). Each
DNA probe was end-labeled with 32P-adenosine triphos-
phate and purified by Sephadex G-25 column chromatog-
raphy before use. Nuclear protein extracts were prepared
from aortic wall specimens and preincubated for 10 min-
utes at room temperature with 0.25 g of poly(dI-dC) in
10 mmol/L Tris-HCl buffer (pH 7.5) containing 50
mmol/L NaCl, 4% glycerol, 0.5 mmol/L dithiothreitol,
0.5 mmol/L ethylenediamine tetraacetic acid (EDTA),
and 1 mmol/LMgCl2, followed by the addition of 25,000
cpm of 32P-labeled specific DNA probe for 20 minutes at
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sis on prerun 4% polyacrylamide gels followed by autora-
diography. The specificity of protein/DNA interactions
was assessed by incubating nuclear protein samples either
with excess unlabeled DNA probe (cold competition) or
with 32P-labeled nonbinding mutant DNA probe. For
supershift assays, nuclear protein extracts were preincu-
bated (30 minutes at room temperature) with 1 g of
antibodies recognizing either p65, for NF-B, or c-Fos, for
AP-1 (Santa Cruz Biochemicals, Santa Cruz, Calif).
Gelatin zymography. Total protein extracts were pre-
pared from aortic tissue samples, mixed with nonreducing
sample buffer containing 0.1% sodium dodecyl sulfate (SDS),
and electrophoretically resolved through 10% polyacrylamide
gels co-polymerizedwith 1mg/mLgelatin substrate (Sigma),
as described in Appendix I (online only) and in previous
reports.16 The relative molecular weight of each proteolytic
band was estimated by the migration positions of known
molecular weight standards (Bio-Rad, Richmond, Calif) and
authentic 92- and 72-kd gelatinase standards, and the relative
amount of each gelatinase activity was estimated by densitom-
etry. To determine whether PDTC had any direct effect on
gelatinase activities, various concentrations of PDTC (0 to
100 mol/L) were included in the substrate buffer before
visualization of proteolytic bands.
Enzyme-linked immunosorbent assays. Aortic pro-
tein extracts and serum samples were analyzed by using
commercially available enzyme-linked immunosorbent as-
say kits specific for mouse interleukin (IL)-1 and IL-6,
according to the manufacturer’s instructions (R&D Sys-
tems, Inc, Minneapolis, Minn). Each of these assays uses a
dual-antibody method with a reported sensitivity of 7.8
pg/mL and no significant cross-reactivity with other cyto-
kines. Spectrophotometric optical density measurements
were made at 450 nm by using an automated microplate
reader (Bio-Tek Instruments, Inc, Winooski, Vt), and the
amount of IL-1 or IL-6 in each sample was determined
from linear standard curves by using recombinant mouse
proteins.
Statistical analysis. Data are presented as the mean
SEM. Between-group comparisons of AD measurements
and calculated AD values were made by using the Mann-
Whitney U test, and the incidence of AAAs was compared
by using the Fisher exact test. Mean histologic scores for
inflammation and elastin content were compared by using
unpaired t tests. Densitometry data (gelatin zymography)
and serum and aortic tissue cytokine concentrations were
compared by using one-way analysis of variance with the
Bonferroni multiple comparisons test. All statistical analy-
ses were performed with InStat3 version 3.0a from Graph-
Pad Software, Inc (San Diego, Calif), and P values .05
were considered significant.
RESULTS
Treatment with PDTC suppresses development of
elastase-induced AAAs. As illustrated in Fig 1, there were
no differences in either preperfusion or immediate postper-
fusion AD measurements between saline- and PDTC-treated mice, but final AD measurements in the PDTC-
treated group were 20% lower than in the saline-treated
controls (P  .0001; Mann-Whitney U test). The median
extent of aortic dilatation immediately after elastase perfusion
was approximately 65% to 70%, with no significant difference
between groups (AD Pre ¡ Post, mean  SEM: PDTC,
66.0% 1.9%; saline controls, 71.7% 2.2%;Mann-Whitney
U test), and this is consistent with our previous studies using
this mouse model (Fig 1, B).16,42-44 Although all animals
exhibited secondary (interval) dilatation over the 14-day ex-
perimental period, the extent of interval dilatation was 53%
less in PDTC-treated mice compared with saline-treated con-
trols (AD Post ¡ Final: PDTC, 26.3%  1.9%; saline,
56.1%  2.9%; P  .0001; Mann-Whitney U test; Fig 1, C).
This difference was further reflected by a 35% decrease in the
overall extent of aortic dilation between PDTC-treated mice
and saline-treated controls (AD Pre ¡ Final: PDTC,
109.8%  4.2%; saline, 169.1%  7.5%; P  .0001; Mann-
Whitney U test), along with a significant difference in the
incidence of AAAs (PDTC, 31 [63%] of 49 mice; saline, 34
[100%] of 34 mice; P  .0001; Fisher exact test; Fig 1, D).
By light microscopy, elastase-induced AAAs in the
saline-treated control group were characterized by an in-
tense transmural inflammatory response accompanied by
destruction of medial elastin (Fig 2). In contrast, the sup-
pression of AAAs in PDTC-treated mice was associated
with preservation of the medial elastic lamellae, decreased
inflammation, and a dense fibrocollagenous response in the
adventitia (Fig 2).
Treatment with PDTC inhibits aortic wall NF-B
and AP-1 DNA-binding activities. In saline-treated
mice, development of elastase-induced AAAs was associ-
ated with a marked increase in aortic wall NF-B/DNA-
binding activity as compared with normal (unperfused)
aorta (Fig 3, A, lanes b and c). In contrast, treatment with
PDTC was associated with suppression of this NF-B/
DNA-binding activity to a level similar to that seen in the
unperfused normal aorta (Fig 3, A, lane d). The specificity
of the DNA-binding activity for NF-B was confirmed by
preincubation with a 100-fold excess of unlabeled NF-B
oligonucleotide probe (cold competitor; Fig 3, A, lane e)
and by assays conducted with a nonbinding mutant NF-B
DNA probe (not shown); there was also a shift in the
dominant NF-B/DNA-binding activity to a slower-mi-
grating species after preincubation with antibody recogniz-
ing the p65 NF-B subunit (Fig 3, A, lane f). Additional
gel-shift assays revealed a substantial increase in AP-1/
DNA-binding activity during development of elastase-
induced AAAs in saline-treated controls as compared with
normal aorta (Fig 3, B, lanes b and c), as well as a pro-
nounced inhibition of aortic wall AP-1/DNA-binding ac-
tivity in mice treated with PDTC (Fig 3, B, lane d). The
specificity of the DNA-binding activity for AP-1 was con-
firmed by assays conducted with either unlabeled AP-1
DNA probe or with a nonbinding mutant AP-1 DNA
probe (not shown), as well as by preincubation with anti-
body recognizing c-Fos, one of the principal protein com-
ponents of the AP-1 complex (Fig 3, B, lane e).
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of MMP-9. By gelatin substrate zymography, aneurysm
development in saline-treated mice was accompanied by an
increase in aortic wall gelatinase activities corresponding to
both MMP-2 and MMP-9 (Fig 3, C, lanes 4 to 6). In
contrast, metallogelatinase activity corresponding to
MMP-9 was significantly less in mice treated with PDTC
(Fig 3, C, lanes 7 to 9). Scanning densitometry confirmed a
significant decrease in the amount of MMP-9 activity after
PDTC treatment compared with saline controls (P .05),
but there was no significant difference in the amount of
MMP-2 activity (Fig 3, D). There was no evidence that the
addition of PDTC to the substrate buffer had any direct
inhibitory effects on metallogelatinase activities up to con-
centrations of 100 mol/L (Fig 3, E).
PDTC treatment suppresses aortic wall cytokine
production. Immunoassays for IL-1 and IL-6 protein
revealed that both of these cytokines were nearly undetect-
able in extracts of normal aortic tissue, but aortic wall
Fig 1. Extent of aortic dilatation. C57BL/6 mice were
aneurysmal degeneration and were treated every 48 hours
Aortic diameter (AD) measurements were obtained b
perfusion; final measurements were obtained on day 14 (
values are shown in parentheses). Statistical comparison
Mann-WhitneyU test. B-D, The extent of aortic dilatatio
between elastase perfusion and death on day 14 (C), an
percentile changes in AD. Data shown represent the m
performed with the nonparametric Mann-WhitneyU tes
significant).concentrations of both IL-1 and IL-6 increased substan-tially with the development of elastase-induced AAAs in
saline-treated mice (Fig 4, A and B). In contrast, the mean
aortic wall concentration of IL-1 was reduced by 66% in
PDTC-treated mice (saline, 65.39  15.98 pg/mg pro-
tein; PDTC, 22.19  6.52 pg/mg protein; P  .05), and
the mean concentration of IL-6 was reduced by 67% (sa-
line, 20.45  3.76 pg/mg protein; PDTC, 6.74  2.64
pg/mg protein; P .05). Similar changes in cytokine levels
were observed in the systemic circulation: serum IL-1
levels increased 2.9-fold, and serum IL-6 levels increased
3.3-fold in saline-treated controls (each P  .05 vs normal
serum; Fig 4, C and D). Mice treated with PDTC exhibited
serum IL-1 levels 42% lower than those of saline-treated
controls (P  .05), and serum IL-6 levels were reduced by
71% (P  .05), to levels equivalent to those found in
normal mouse serum.
DISCUSSION
NF-B transcription factors play a vital role in cellular
cted to transient aortic perfusion with elastase to induce
either saline or pyrrolidine dithiocarbamate (PDTC).A,
(AD Pre) and immediately after (AD Post) elastase
inal). Data shown represent the mean SEM (median
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Volume 41, Number 3 Parodi et al 483emia/reperfusion injury, and oxidant stress.32,33 NF-B is
normally sequestered in the cytoplasm as an inactive com-
plex of p50 and/or p65 protein subunits, where it is bound
to a member of the endogenous inhibitor of NF-B (IB)
family. Cellular activation by lipopolysaccharide, cytokines,
or oxidative stress leads to serine phosphorylation of IB,
whereupon IB is ubiquitinated and targeted for degrada-
tion in the proteasome. Upon release from IB, active
Fig 2. Aortic wall structure. Representative micrograph
aorta and aortas from mice 14 days after elastase perfus
dithiocarbamate (PDTC). All sections were stained with
the left and high-power views (100	) shown on the rig
C, Day 14 after elastase; PDTC treatment. D and E, H
inflammation (D) and the integrity of aortic elastin (E) o
treatment groups. Data represent the mean  SEM of
Comparisons were made with the unpaired (two-tailed)NF-B complexes rapidly translocate to the cell nucleus,where they bind to specific DNA elements (B sites) found
within the promoter regions of many different genes; this
results in activation of gene transcription. Previous stud-
ies indicate that NF-B activation can be inhibited by
PDTC and other antioxidant agents to reduce expression
of NF-B–responsive gene products, including IL-1,
IL-6, and metalloproteinases (eg, MMP-1, MMP-3, and
MMP-9), and that treatment with PDTC improves out-
ortic wall cross sections taken from normal (unperfused)
nd treatment with either saline (control) or pyrrolidine
oeff-van Gieson, with low-power views (20	) shown on
Normal aorta. B, Day 14 after elastase; saline controls.
logic sections were scored for the extent of aortic wall
e-point scale, by four different examiners unaware of the
logic scores for three different animals in each group.
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March 2005484 Parodi et alFig 3. Aortic wall nuclear factor-B (NF-B), activator protein (AP)-1, and metalloproteinase (MMP) activities. A
and B, Gel-shift assays for NF-B (A) and AP-1 (B). DNA-binding activities were performed with nuclear protein
extracts from normal aorta and aortas from mice 14 days after elastase perfusion and treatment with either saline or
pyrrolidine dithiocarbamate (PDTC). Control incubations included an excess of unlabeled DNA probe (competitor)
and supershifts with antibodies recognizing p65 for NF-B or c-Fos for AP-1 (arrows). C, Gelatin zymograms
performed with total protein extracts showing increased proteinase activity corresponding to MMP-2 and MMP-9 14
days after elastase perfusion in saline-treated controls, but showing diminished MMP activities in animals treated with
PDTC (triplicate samples shown).D, Scanning densitometry of bands corresponding toMMP-9 andMMP-2 in gelatin
zymograms, demonstrating a significant reduction in the amount of MMP-9 activity in aortic extracts from PDTC-
treated mice compared with saline-treated controls. Data shown represent the mean  SEM (n  3 for each group).
Statistical comparisons were made with one-way analysis of variance with the Student-Newman-Keuls multiple
comparisons test (*P  .05 vs normal aorta and †P  .05 vs PDTC-treated group). E, Gelatin zymograms containing
MMP-2 and MMP-9 activities (aortic extracts from day 14 saline-treated mice) were incubated in vitro with substrate
buffers containing varying concentrations of PDTC; they demonstrated no direct inhibition of gelatinase activities.
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we demonstrated for the first time that treatment of mice
with PDTC suppresses the development of experimental
aortic aneurysms in an elastase-induced mouse model. Fur-
thermore, the aneurysm-suppressing effects of PDTC were
accompanied by diminished aortic tissue NF-B and AP-1
DNA-binding activities; inhibition of aortic wall IL-1,
IL-6, and MMP-9 expression; and marked reductions in
aortic wall inflammation and connective tissue destruction.
These findings provide support for the functional impor-
tance of oxidative stress and sustained NF-B activation
within aortic wall tissue during the development of AAAs
and suggest that NF-B plays a central role in orchestrating
the deleterious tissue responses that underlie progressive
aneurysmal degeneration.
Electrophoretic gel-shift assays demonstrated increased
activation of NF-B and AP-1 transcription factor activities
Fig 4. Aortic tissue and serum cytokine levels. Interleu
enzyme-linked immunosorbent assay in aortic tissue extr
mice and mice treated with either saline or pyrrolidine d
Data shown represent the mean SEM (n 5 for all gro
of variance with the Bonferroni multiple comparisons te
controls).within aortic wall tissue during the development of elastase-induced AAAs and showed that treatment with PDTC was
associated with inhibition of both NF-B and AP-1. Al-
though signal-dependent activation of transcription factors
is often an early and transient event in stimulated cells, the
upregulation of NF-B and AP-1 observed in day 14 AAAs
indicates that activation of these transcription factors is
likely a sustained response during the pathophysiologic
development of aortic aneurysms. Gel-shift assays demon-
strating that treatment with PDTC inhibited NF-B activ-
ity were also consistent with the known and expected
effects of this compound, and, to the extent that these
findings reflect overall transcription factor activity in the
dominant cell types present in aneurysm tissue, effective
inhibition of NF-B and AP-1 most likely occurred in
macrophages, themost prevalent cell type in these lesions at
the 14-day interval examined. Furthermore, the observed
reduction in aortic wall expression of IL-1, IL-6, and
 and interleukin-6 concentrations were measured by
and B) and serum (C and D) for normal (unperfused)
carbamate (PDTC) for 14 days after elastase perfusion.
Statistical comparisons were made with one-way analysis
 .05 vs normal and †P  .05 vs day 14 saline-treatedkin-1
acts (A
ithio
ups).
st (*PMMP-9 is consistent with this interpretation, because mac-
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molecules in the elastase-induced mouse model of AAAs. It
is nonetheless clear that gel-shift assays performed on nu-
clear protein extracts from aortic tissue reflect the sum of
protein/DNA-binding interactions from a complex mix-
ture of cells; thus, the results of these experiments are not as
easily interpreted as those of studies performed in isolated
cell types, and our data cannot distinguish among events
occurring in infiltrating cell types (macrophages and lym-
phocytes), resident aortic wall mesenchymal cells (smooth
muscle cells and fibroblasts), or circulating progenitor cells
that may accumulate in damaged aortic tissue. Further
study will therefore be needed to elucidate the time course
of aortic wall NF-B activation in elastase-induced AAAs,
the cell types in which NF-B activation is most prominent,
and the potential resolution of NF-B activation that might
occur with stabilization of the aneurysm wall at later time
intervals.
Suppression of AAAs by treatment with PDTC was
associated with preservation of aortic wall elastin and an
enhanced fibrocollagenous response within the adventitia.
Although PDTC did not completely prevent inflammatory
cell infiltration into the elastase-injured aorta, its use was
associated with a significant decrease in inflammation and
reduced aortic expression of MMP-2 and MMP-9, two of
the most prominent elastin-degrading metalloproteinases
normally present in AAAs. Although PDTC is known to
have metal ion–chelating effects and MMPs are zinc-
dependent enzymes, in vitro experiments with gelatin zy-
mography revealed no direct inhibition of metallogelati-
nase activities by PDTC. Because pharmacologic inhibition
or gene targeting of these MMPs also leads to suppression
of AAAs, the observed preservation of aortic wall connec-
tive tissue seems most consistent with a PDTC-mediated
reduction in NF-B–stimulated macrophage MMP expres-
sion.We also observed that treatment with PDTC inhibited
IL-1 and IL-6 production in elastase-induced AAAs. Be-
cause the IL-1 and IL-6 genes are both highly responsive
to activation by NF-B, it is most likely that PDTC inhib-
ited these cytokines through an NF-B–related effect. Be-
cause IL-1 and IL-6 are also known to induce AP-1 and
MMP gene expression, decreased cytokine expression
might have contributed to the overall suppression of MMP
production. Indeed, the importance of these cytokines in
experimental aneurysmal degeneration is illustrated by our
recent findings that mice with targeted disruption of either
IL-1 type I receptor or IL-6 genes are resistant to the
development of elastase-induced AAAs (Thompson et al,
unpublished data, 2004). PDTC-mediated inhibition of
NF-Bmay therefore have had a potent synergistic effect in
suppressing macrophage MMP-9 production by direct in-
hibition of NF-B and by indirect inhibition of cytokine-
induced AP-1 activation.
Several recent investigations have highlighted the im-
portance of oxidative stress and ROS in the pathophysiol-
ogy of AAAs.8,45,46 Because PDTC is an antioxidant, as
well as a specific inhibitor of NF-B activation, we cannot
exclude the possibility that PDTC exerted its aneurysm-suppressing effects in part through inhibition of ROS-
induced events. However, recent evidence indicates that
PDTC suppresses NF-B through mechanisms that are
independent of its antioxidant activity.47 PDTC treatment
was also specifically associated with reduced NF-B DNA-
binding activity and reduced AP-1 activity; because PDTC
has actually been reported to activate AP-1 in other sys-
tems,48-50 this suggests that inhibition of NF-B super-
seded any activation of AP-1 that might otherwise have
occurred within the elastase-injured mouse aorta. More-
over, because it has been shown that NF-B activation is
required for maximal induction of MMP-9 transcription in
some experimental systems,25-28 these considerations em-
phasize the important role played by NF-B in MMP-9
induction in vivo.
Two recent reports provided the first direct evidence
that NF-B activation plays a role in experimental AAAs.
For example, Nakashima et al30 demonstrated nuclear lo-
calization of p65 protein (activated NF-B) in adventitial
macrophages in human AAA tissues and then used an
elastase-induced rat model of AAAs combined with periad-
ventitial administration of a decoy oligodeoxynucleotide to
block NF-B and ets transcriptional activities. These exper-
iments demonstrated effective inhibition of AAAs, along
with suppression of aortic wall MMP-9 expression, as a
consequence of NF-B inhibition. More recently, Law-
rence et al31 used a similar elastase-induced rat model to
examine the effects of treatment with the immunosuppres-
sant drug rapamycin. They also observed a significant re-
duction in aortic dilatation, as well as suppression of NF-B
activity and inhibition of MMP-9 production. Our study
therefore confirms the hypothesis that NF-B is a pivotal
molecular mediator in aneurysm disease, using a different
pharmacologic strategy, and reinforces the specific role of
NF-B in regulating MMP-9 expression during aortic wall
inflammatory responses. Our results also support the no-
tion that therapeutic approaches targeting NF-B may be
an especially promising strategy to achieve suppression of
aneurysmal degeneration.
APPENDIX I. Extended methods
Elastase perfusion model. Mice weighing 20 to 25 g
were anesthetized with 55 to 60 mg/kg intraperitoneal
sodium pentobarbital, and a laparotomy was performed
under sterile conditions. The abdominal aorta was isolated
with the assistance of an operating stereomicroscope
(Leica), and the preperfusion AD was measured with a
calibrated ocular grid. After temporary ligatures were
placed around the proximal and distal aorta, an aortotomy
was created at the bifurcation by using the tip of a 30-gauge
needle. A heat-tapered segment of PE-10 polyethylene
tubing was introduced through the aortotomy and secured,
and the aortic lumen was perfused for 5 minutes at 100mm
Hg with saline containing type I porcine pancreatic elastase
(0.414 U/mL; Sigma). After the perfusion catheter was
removed, the aortotomy was repaired without constriction
of the lumen, and the AD Post was measured 5 minutes
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were allowed free access to food and water for 14 days.
Light microscopy. Specimens of the abdominal aorta
were excised after systemic perfusion/fixation with 10%
neutral buffered formalin (120mmHg for 10minutes) and
embedded in paraffin. Cross sections of aortic tissue (5m)
were stained with Verhoeff-van Gieson for elastin and
examined by light microscopy. The extent of aortic wall
inflammation and the integrity of aortic wall elastin were
each estimated with histologic scoring by using sections
taken from mice 14 days after elastase perfusion and treat-
ment with either saline or PDTC. Sections from three
animals in each group were scored for the extent of inflam-
mation and elastin content by four different observers who
were unaware of the experimental group. The scoring
system for aortic inflammation was based on a one- to
five-point scale, with 1 representing no inflammation and 5
representing a severe transmural inflammatory response. A
similar one- to five-point scale was used to score aortic wall
elastin content, with 1 representing no detectable elastin
and 5 representing normal-appearing elastic lamellae. Indi-
vidual histologic scores for each animal were based on the
average scores obtained by examination of four high-power
(100	) fields per examiner, and the average scores for three
animals in each experimental group were used to determine
the mean  SEM histologic scores for that group. Com-
parisons of the mean inflammation and elastin content
scores between PDTC- and saline-treated mice were made
by using the unpaired t test.
Electrophoretic gel shift assays. To evaluate activa-
tion of NF-B and AP-1 transcription factors during the
development of AAAs, nuclear protein extracts were pre-
pared from aortic wall specimens obtained before or 14
days after elastase perfusion in PDTC- or saline-treated
mice. A DNA probe corresponding to the murine NF-B/
c-Rel recognition element was prepared that consisted of a
double-stranded oligodeoxynucleotide with 5=-AGT TGA
GGG GAC TTT CCC AGG C-3= as the top strand and
5=-GCC TGG GAA AGT CCC CTC AAC T-3= as the
complementary strand. As a control, a nonbinding mutant
NF-B probe was prepared with 5=-AGT TGA GGc GAC
TTT CCC AGG C-3= as the top strand and 5=-GCC TGG
GAA AGT CgC CTC AAC T-3= as the complementary
strand. A DNA probe was also prepared to correspond to
the murine AP-1 recognition element: it consisted of a
double-stranded oligodeoxynucleotide with 5=-CGC TTG
ATG ACT CAG CCG GAA-3= as the top strand and
5=-TTC CGG CTG AGT CAT CAA GCG-3= as the com-
plementary strand, and a nonbinding mutant AP-1 probe
was prepared with 5=-CGC TTG ATG ACT tgG CCG
GAA-3= as the top strand and 5=-TTCCGGCca AGTCAT
CAA GCG-3= as the complementary strand. Each DNA
probe was end-labeled by using T4 polynucleotide kinase in
the presence of 32P-adenosine triphosphate and purified by
Sephadex G-25 column chromatography before use. Nu-
clear protein samples (10 g in a 10-L reaction volume)
were preincubated for 10 minutes at room temperature
with 0.25 g of poly(dI-dC) in 10 mmol/L Tris-HClbuffer (pH 7.5) containing 50 mmol/L NaCl, 4% glycerol,
0.5 mmol/L dithiothreitol, 0.5 mmol/L EDTA, and 1
mmol/L MgCl2, followed by the addition of 25,000 cpm
of 32P-labeled specific DNA probe and incubation for 20
minutes at room temperature. Samples were resolved by
electrophoresis (200 V for 4 hours) on prerun 4% polyacryl-
amide gels followed by autoradiography. To assess the
specificity of protein/DNA interactions, nuclear protein
samples were incubated with a 100-fold excess of unlabeled
DNA probe (cold competition) or with labeled nonbinding
mutant DNA probes. For supershift assays, before incuba-
tion with the corresponding DNA probe, the nuclear pro-
tein extracts were incubated for 30 minutes at room tem-
perature with 1 g of antibodies recognizing the NF-B
p65 subunit or with antibodies recognizing c-Fos for AP-1
(Santa Cruz Biochemicals).
Gelatin zymography. To assess aortic wall expression
of MMP-2 and MMP-9, frozen aortic tissue samples were
pulverized under liquid nitrogen and extracted in ice-cold
50 mmol/L Tris-HCl buffer (pH 7.5) containing 1.0
mol/L NaCl, 2.0 mol/L urea, 0.1% EDTA, and 0.1%
(wt/vol) Brij-35. After centrifugation at 10,000g for 1
hour at 4°C, the supernatant was dialyzed overnight against
50 mmol/L Tris HCl (pH 8.0), 1.0 mol/L NaCl, and 20
mmol/L CaCl2 by using a 12,000 to 14,000 molecular
weight cutoff membrane. The total protein concentration
of each sample was determined by using an assay kit pur-
chased from Bio-Rad (Hercules, Calif). Protein-normal-
ized samples were mixed with nonreducing sample buffer
containing 0.1% SDS and were then electrophoretically
resolved through 10% polyacrylamide gels co-polymerized
with 1mg/mL gelatin substrate (Sigma). Gels were washed
free of SDS with 2.5% Triton X-100 and incubated over-
night at 37°C in a substrate buffer containing 50 mmol/L
Tris-HCl (pH 8.5), 5 mmol/L CaCl2, and 0.02% NaN3.
After staining with 0.1% Coomassie blue R-250 in 40%
methanol/10% acetic acid, gelatinase activities were ob-
served as clear bands against a dark background of intact
substrate. The relative molecular weight of each proteolytic
band was estimated by the migration positions of known
molecular weight standards (Bio-Rad, Richmond, Calif)
and authentic 92- and 72-kd gelatinase standards, and the
relative amount of each gelatinase activity was estimated by
densitometry. To determine whether PDTC had any direct
effect on gelatinase activities, various concentrations of
PDTC (0 to 100 mol/L) were included in the substrate
buffer before visualization of proteolytic bands.
Enzyme-linked immunosorbent assays. To com-
pare systemic and aortic wall cytokine production during
aneurysm development in PDTC- and saline-treated mice,
serum and aortic protein extracts were analyzed with com-
mercially available enzyme-linked immunosorbent assay
kits specific for mouse IL-1 and IL-6 (R&D Systems).
Each of these assays uses a dual-antibody method with a
reported sensitivity of 7.8 pg/mL and no significant cross-
reactivity with other cytokines. Spectrophotometric optical
density measurements were made at 450 nm by using an
automated microplate reader (Bio-Tek Instruments), and
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mined from linear standard curves by using recombinant
mouse proteins.
Statistical analysis. Data are presented as the mean
SEM. Between-group comparisons of AD measurements
and calculated AD values were made with the Mann-
Whitney U test, and the incidence of AAAs was compared
by using the Fisher exact test. Mean histologic scores for
inflammation and elastin content were compared by using
unpaired t tests. Densitometry data (gelatin zymography)
and serum and aortic tissue cytokine concentrations were
compared by using one-way analysis of variance with the
Bonferroni multiple comparisons test. All statistical analy-
ses were performed with InStat3 version 3.0a from Graph-
Pad Software, and P values .05 were considered signifi-
cant.
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